Skip To Main Content
Roshni Deepa Kalachand on Muck Rack

Roshni Deepa Kalachand

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Roshni Deepa

Contact Roshni Deepa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prevalence of BRCA1/2 variants in an Ovarian Cancer Cohort: outcomes from a Nationwide Testing Program

|
By Ciara S. McNevin, Kate Murphy Verified, Pierre Murchan, Orla Fitzpatrick, Sharon O’Toole, Paul Smyth, Emer Atkinson, Anne-Marie Baird, Steven Gray, Cathal Ó’Brien, Trudi McDevitt, Brendan Doyle, Niamh Coleman, Stephen Finn, Karen A Cadoo, Andrea Hennessy, Georgia Thodi, Roshni Deepa Kalachand
| Nature Verified
Abstract Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the management of BRCA1- and BRCA2-associated ovarian cancer (OC). In 2020, Ireland implemented a nationwide, oncology-led pathway for mainstreamed BRCA1/2 testing in patients with OC. This study evaluated the pathway and characterised the BRCA1/2 landscape in an Irish cohort of patients with OC. Samples collected between January 2020 and December 2023 were tested in two national molecular diagnostic laboratories.
Open in Who Shared Issue with article?
See all 1 articles